tbuckley/cabot-search huggingface dataset:
Does Insurance Status Interfere with Outcomes in Patients with Hodgkin and Non-Hodgkin Lymphoma?: The UT Health San Antonio Experience
Authors: Juan F Garza, Michelle Janania Martinez, Prathibha Surapaneni, Tyler W Snedden, Snegha Ananth, David J Gregorio, Sushanth Kakarla, Jeremy Rawlings, Joel E Michalek, Qianqian Liu, Adolfo Enrique Diaz
Journal: Blood (2019)
177Lu-PSMA and 177Lu-DOTATATE Therapy in a Patient With Metastatic Castration-Resistant Prostate Cancer and Neuroendocrine Differentiation
Authors: Majid Assadi, Elahe Pirayesh, Seyed Javad Rekabpour, Farshad Zohrabi, Esmail Jafari, Iraj Nabipour, Abdolhamid Esmaili, Abdullatif Amini, Hojjat Ahmadzadehfar
Journal: Clinical Nuclear Medicine (2019)

We presented a promising result of radionuclide therapy using Lu-PSMA and Lu-DOTATATE in a patient with prostatic adenocarcinoma and neuroendocrine differentiation. Functional imaging of somatostatin receptors in patients with metastatic castration-resistant prostate cancer may pave the way toward implementation of novel radionuclide targets for the treatment of this aggressive subtype of prostate cancer.
CC-92480 Is a Novel Cereblon E3 Ligase Modulator with Enhanced Tumoricidal and Immunomodulatory Activity Against Sensitive and Resistant Multiple Myeloma Cells
Authors: Antonia Lopez-Girona, Courtney G. Havens, Gang Lu, Emily Rychak, Derek Mendy, Bonny Gaffney, Christine Surka, Chin-Chun Lu, Mary Matyskiela, Gody Khambatta, Lilly Wong, Joshua Hansen, Daniel W. Pierce, Brian E. Cathers, James Carmichael
Journal: Blood (2019)
Editing a γ-Globin Repressor Binding Site Restores Fetal Hemoglobin Synthesis and Corrects the Phenotype of Sickle Cell Disease Erythrocytes
Authors: Leslie Weber, Giacomo Frati, Tristan Felix, Clara Wollenschlaeger, Antonio Casini, Vasco Meneghini, Cecile Masson, Anne De Cian, Anne Chalumeau, Fulvio Mavilio, Mario Amendola, Isabelle André, Anna Cereseto, Wassim El Nemer, Jean-Paul Concordet, Carine Giovannangeli, Marina Cavazzana, Annarita Miccio
Journal: Blood (2019)
Pulmonary Function Tests Reveal Unrecognized Lung Dysfunction and Have Independent Prognostic Significance in Patients with Systemic AL Amyloidosis
Authors: Eftathios Kastritis, Georgia Trakada, Despina Fotiou, Magdalini Migkou, Maria Gavriatopoulou, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Ioanna Dialoupi, Ioannis Ntanasis-Stathopoulos, Despina Mparmparousi, Aikaterini Xirokosta, Evangelos Terpos, Meletios A. Dimopoulos
Journal: Blood (2019)
The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results
Authors: David A Sallman, Adam S. Asch, Monzr M. Al Malki, Daniel J. Lee, William B. Donnellan, Guido Marcucci, Suman Kambhampati, Naval G. Daver, Guillermo Garcia-Manero, Rami S. Komrokji, Joanna Van Elk, Ming Lin, Jens-Peter Volkmer, Chris H Takimoto, Mark Chao, Paresh Vyas
Journal: Blood (2019)
Measuring social and occupational functioning of people with bipolar disorder: A systematic review
Authors: Nadia Akers, Fiona Lobban, Claire Hilton, Katerina Panagaki, Steven H. Jones
Journal: Clinical Psychology Review (2019)

Previous literature has focused on impaired social and occupational functioning in Bipolar Disorder (BD), however this ignores people who may be functioning well or even exceptionally. This paper presents the first systematic review of how functioning is measured and the range of functioning observed in BD to aid applied research and practice in this area. Identified measures from studies reporting use of a social and/or occupational functioning measure in BD were organised according to frequency of use over the last 10 years, resulting in six measures (Global Assessment of Functioning (GAF), Functioning Assessment Short Test (FAST), Social and Occupational Functioning Scale (SOFAS), Social Adjustment Scale (SAS)), Social Functioning Scale (SFS) and LIFE-Range of Impaired Functioning (LIFE-RIFT). Descriptive statistics of sample scores were extracted and pooled to provide cross-study values for each measure. Around 16% of individuals with BD can be estimated to function at a high level, defined as those falling within two standard deviations of the mean score on each measure. Evidence of a ceiling effect for some measures suggests that BD functioning may have been underestimated during measure development. Future research is needed to further understand higher functioning in people with BD, and factors which may support this.
NLRP6 Expression By the Hosts Enhances the Severity of Experimental Graft-Versus-Host Disease (GVHD)
Authors: Tomomi Toubai, Hiroya Tamaki, Corinne Rossi, Katherine Oravecz-Wilson, Chen Liu, Nathan Mathewson, Yaping Sun, Grace Chen, Pavan Reddy
Journal: Blood (2014)
ATIM-29. IDENTIFYING IMMUNOLOGICAL BARRIERS TO IMMUNOTHERAPY IN PATIENTS WITH GLIOBLASTOMA MULTIFORME
Authors: Michael Gustafson, Ian Parney, Allan Dietz
Journal: Neuro-Oncology (2019)

Abstract Recent successes in cancer immunotherapy have provided new avenues for the treatment of glioblastoma multiforme (GBM). Several immunotherapeutic approaches are now being utilized to treat patients with GBM including checkpoint inhibition, autologous/CAR-T cell therapy, and cancer vaccines. Preliminary data suggests that the majority of patients have sub-optimal clinical responses to these therapies. The impaired anti-tumor immune responses observed in these patients are likely a consequence of immune system dysfunction contributed to by a variety of factors that include diminished antigen presentation/detection, leukopenia, alterations in cytokine levels and cellular mediators. We have previously demonstrated that patients with GBM exhibit profound immune suppression resulting from both tumor and treatment related effects via a comprehensive quantitation of peripheral blood leukocytes by flow cytometry. We hypothesize that the depth and breadth of immunosuppression will significantly affect responses to immunotherapy. Prominent phenotypic abnormalities observed in GBM patients include elevated levels of CD14+HLA-DRlo/neg monocytes and reduced absolute CD4 T cell counts. We will present data how these and other phenotypes may potentially influence responses to patients treated with dendritic cell vaccines. Our goal is to understand the role of these cells in the context of immunosuppression not only to facilitate the development of targeted immunotherapies to circumvent their effects, but also to potentially utilize them as biomarkers for understanding diverse responses to immunotherapies.
Cell of Origin Classification of DLBCL Using Targeted NGS Expression Profiling and Deep Learning
Authors: Maher Albitar, Zijun Yidan Xu-Monette, Babak Shahbaba, Ivan De Dios, Yingjun Wang, Deng Manman, Alexandar Tzankov, Carlo Visco, Govind Bhagat, Karen Dybkær, Wayne Tam, Eric D. Hsi, Maurilio Ponzoni, Andres JM Ferreri, Michael Moller, Miguel A. Piris, Joannes H.J.M. Van Krieken, Youli Zu, Wanlong Ma, Hagop M. Kantarjian, Yong Li, Ken H. Young
Journal: Blood (2019)
Outcomes of AML Patients Treated with Gemtuzumab-Ozogamicin Based Therapies: A Cue to Optimal Chemotherapy Backbone
Authors: Swapna Thota, Abhay Singh, Sarah Sadek, Mark G. Faber, Jeffrey Baron, Amro Elshoury, James E. Thompson, Amanda Przespolewski, Elizabeth A. Griffiths, Eunice S. Wang
Journal: Blood (2019)
Factors Associated With Oncologist Discussions of the Costs of Genomic Testing and Related Treatments
Authors: K Robin Yabroff, Jingxuan Zhao, Janet S de Moor, Helmneh M Sineshaw, Andrew N Freedman, Zhiyuan Zheng, Xuesong Han, Ashish Rai, Carrie N Klabunde
Journal: JNCI Journal of the National Cancer Institute (2019)

Use of genomic testing is increasing in the United States. Testing can be expensive, and not all tests and related treatments are covered by health insurance. Little is known about how often oncologists discuss costs of testing and treatment or about the factors associated with those discussions.We identified 1220 oncologists who reported discussing genomic testing with their cancer patients from the 2017 National Survey of Precision Medicine in Cancer Treatment. Multivariable polytomous logistic regression analyses were used to assess associations between oncologist and practice characteristics and the frequency of cost discussions. All statistical tests were two-sided.Among oncologists who discussed genomic testing with patients, 50.0% reported often discussing the likely costs of testing and related treatments, 26.3% reported sometimes discussing costs, and 23.7% reported never or rarely discussing costs. In adjusted analyses, oncologists with training in genomic testing or working in practices with electronic medical record alerts for genomic tests were more likely to have cost discussions sometimes (odds ratio [OR] = 2.09, 95% confidence interval [CI] = 1.19 to 3.69) or often (OR = 2.22, 95% CI = 1.30 to 3.79), respectively, compared to rarely or never. Other factors statistically significantly associated with more frequent cost discussions included treating solid tumors (rather than only hematological cancers), using next-generation sequencing gene panel tests, having higher patient volume, and working in practices with higher percentages of patients insured by Medicaid, or self-paid or uninsured.Interventions targeting modifiable oncologist and practice factors, such as training in genomic testing and use of electronic medical record alerts, may help improve cost discussions about genomic testing and related treatments.
Revised-MALT-IPI: A New Predictive Model That Identifies High-Risk Patients with Extranodal Marginal Zone Lymphoma (EMZL)
Authors: Juan Pablo Alderuccio, Isildinha M Reis, Thomas M. Habermann, Brian K. Link, Catherine Thieblemont, Annarita Conconi, Melissa C Larson, Luciano Cascione, Wei Zhao, James R. Cerhan, Emanuele Zucca, Izidore S. Lossos
Journal: Blood (2019)
TMIC-19. H+ EXTRUSION PROTEIN NA/H EXCHANGER IN METABOLIC POLARIZATION OF GLIOMA-ASSOCIATED MICROGLIA/MACROPHAGES AND TUMOR IMMUNITY
Authors: Md Nabiul Hasan, Xiudong Guan, Avani Ahuja, Maria Castro, Gary Kohanbash, Dandan Sun
Journal: Neuro-Oncology (2019)

Abstract Immunosuppressive tumor microenvironment (TME) in glioblastoma (GBM) attributes to poor efficacy of chemotherapy and/or immunotherapy. We recently reported that SLC9A1 gene expression (Na/H exchanger 1, NHE1) in GBM tumor correlates with increased macrophage tumor infiltration and worsened patient survival. Temozolomide (TMZ) monotherapy, the standard care therapy for GBM, stimulates NHE1 protein expression in mouse syngeneic glioma models. We speculate that in response to TMZ therapy, NHE1 promotes immunosuppressive TME development via deregulation of glucose metabolism and anti-tumor function of immune cells. CD57BL/6 mice bearing GL26 glioma tumor were treated with NHE1 inhibitor HOE-642 (H, 0.3 mg/kg/day), TMZ (T, 2.5 mg/kg/day), and/or anti-PD-1 (10 mg/kg/day) monotherapy or in combination. The T+H+anti-PD-1 combination therapy increased glucose uptake (2-NBDG) and mitochondrial mass (mitotracker fluorescent intensity) of tumor infiltrating CD8+ T-cells by ~2-fold compared to the monotherapies. This suggests that NHE1 protein is involved in metabolic transformation of T-cells and affects their responses to chemo and/or immunotherapy. Furthermore, we detected that specific deletion of Nhe1 in Cx3Cr1CreErT2r+/-;Nhe1f/f mice (Nhe1 KO) alters activation of glioma-associated microglia/macrophages (GAM) and T-cells in response to TMZ therapy. TMZ monotherapy stimulated macrophage (CD11b+CD45hi) infiltration by ~2.5-fold in Cx3Cr1CreErT2-/-;Nhe1f/f (Nhe1 Con) mice bearing SB28-GFP glioma tumor with abundant proinflammatory CD16/32+ GAMs. In contrast, TMZ treated Nhe1 KO mice displayed ~3-fold reduction in tumor infiltrating GAMs with nearly abolished Ym-1+ tolerogenic macrophages, ~3-fold reduction of tumor-promoting CD4+CD25+FoxP3+ regulatory T-cells (Treg) and increased CD8+/Treg ratio by ~2-fold than the Nhe1 Con mice. Importantly, TMZ followed by anti-PD-1 therapy prolonged survival of Nhe1 KO mice but not Nhe1 Con mice. Taken together, our study suggests that NHE1 is involved in transformation of GAMs and PD-1 check point activation of T-cells. Blocking NHE1 function in combination with TMZ and anti-PD-1 may restore glucose metabolism of immune cells necessary for their anti-tumor function.
RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia
Authors: Christina A. Snider, Kevin Fung, Francesca Gould, Vera Adema, Cassandra M Kerr, Sunisa Kongkiatkamon, Hassan Awada, Milo Co, Teodora Kuzmanovic, Bhumika J. Patel, Aaron T. Gerds, Sudipto Mukherjee, Aziz Nazha, Hetty E. Carraway, Tomas Radivoyevitch, Jaroslaw P. Maciejewski, Valeria Visconte, Mikkael A. Sekeres, Anjali S. Advani
Journal: Blood (2019)
PATH-07. MITOTIC INDEX THRESHOLDS DO NOT PREDICT CLINICAL OUTCOME FOR IDH-MUTANT ASTROCYTOMA
Authors: Rebecca Yoda, Troy Marxen, Lauren Longo, Chibawanye Ene, Hans-Georg Wirsching, Dirk Keene, Eric Holland, P J Cimino
Journal: Neuro-Oncology (2019)

Abstract Current histological grading recommendations for isocitrate dehydrogenase (IDH)-mutant astrocytoma are imprecise and not reliably predictive of patient outcome, while somatic copy number alterations are emerging as important prognostic biomarkers. One explanation for this relative underperformance of histological grading is that current criteria to distinguish World Health Organization (WHO) grade III anaplastic astrocytomas from lower-grade diffuse astrocytomas (WHO grade II) are vague (‘increased mitotic activity’). This qualitative approach ensures diagnostic uncertainty and a broad ‘gray zone’ where both diffuse and anaplastic designations can reasonably be assigned. Thus, we hypothesized that interobserver variability and lack of defined mitotic thresholds for IDH-mutant astrocytomas underlies poor predictive accuracy of current histologic grading approaches. To test this hypothesis, we quantified total mitotic figures and maximum mitotic activity per ten high-powered fields in an institutional cohort of IDH-mutant astrocytomas. In our cohort, there was no mitotic activity threshold that was reflective of clinical progression-free or overall survival. Furthermore, in a multivariate Cox regression model consisting of mitotic activity, molecular markers, and clinical characteristics, only CDKN2A deletion was identified as a relevant variant for poor overall survival. We conclude that lack of defined mitotic figure thresholds may not contribute to underperformance of histological grading for IDH-mutant astrocytomas. This study supports the shift towards ‘molecular grading’ to replace traditional histological grading for IDH-mutant astrocytomas.
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Authors: Aurelien Marabelle, Dung T. Le, Paolo A. Ascierto, Anna Maria Di Giacomo, Ana De Jesus-Acosta, Jean-Pierre Delord, Ravit Geva, Maya Gottfried, Nicolas Penel, Aaron R. Hansen, Sarina A. Piha-Paul, Toshihiko Doi, Bo Gao, Hyun Cheol Chung, Jose Lopez-Martin, Yung-Jue Bang, Ronnie Shapira Frommer, Manisha Shah, Razi Ghori, Andrew K. Joe, Scott K. Pruitt, Luis A. Diaz Jr
Journal: Journal of Clinical Oncology (2019)

Genomes of tumors that are deficient in DNA mismatch repair (dMMR) have high microsatellite instability (MSI-H) and harbor hundreds to thousands of somatic mutations that encode potential neoantigens. Such tumors are therefore likely to be immunogenic, triggering upregulation of immune checkpoint proteins. Pembrolizumab, an anti‒programmed death-1 monoclonal antibody, has antitumor activity against MSI-H/dMMR cancer. We report data from the phase II KEYNOTE-158 study of pembrolizumab in patients with previously treated, advanced noncolorectal MSI-H/dMMR cancer.Eligible patients with histologically/cytologically confirmed MSI-H/dMMR advanced noncolorectal cancer who experienced failure with prior therapy received pembrolizumab 200 mg once every 3 weeks for 2 years or until disease progression, unacceptable toxicity, or patient withdrawal. Radiologic imaging was performed every 9 weeks for the first year of therapy and every 12 weeks thereafter. The primary end point was objective response rate per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as assessed by independent central radiologic review.Among 233 enrolled patients, 27 tumor types were represented, with endometrial, gastric, cholangiocarcinoma, and pancreatic cancers being the most common. Median follow up was 13.4 months. Objective response rate was 34.3% (95% CI, 28.3% to 40.8%). Median progression-free survival was 4.1 months (95% CI, 2.4 to 4.9 months) and median overall survival was 23.5 months (95% CI, 13.5 months to not reached). Treatment-related adverse events occurred in 151 patients (64.8%). Thirty-four patients (14.6%) had grade 3 to 5 treatment-related adverse events. Grade 5 pneumonia occurred in one patient; there were no other treatment-related fatal adverse events.Our study demonstrates the clinical benefit of anti-programmed death-1 therapy with pembrolizumab among patients with previously treated unresectable or metastatic MSI-H/dMMR noncolorectal cancer. Toxicity was consistent with previous experience of pembrolizumab monotherapy.
Morbidity, Mortality, and Healthcare Utilization in a National Cohort of Pediatric Patients with Hemophagocytic Lymphohistiocytosis Who Received Hematopoietic Stem Cell Transplant
Authors: Archana Ramgopal, Meghan McCormick, Ram Kalpatthi, Louis Rapkin, James Zullo, Steven William Allen
Journal: Blood (2019)
Antimalarial-Induced Cardiomyopathy Resembles Fabry Disease on Cardiac MRI
Authors: Kate Hanneman, Hugo Vidal Alberdi, Gauri Rani Karur, Kostantinos Tselios, Paula J. Harvey, Dafna D. Gladman, Shadi Akhtari, Tosin Osuntokun, Rachel M. Wald, Paaladinesh Thavendiranathan, Jagdish Butany, Murray B. Urowitz
Journal: JACC. Cardiovascular imaging (2019)
Treatment of Acute Poisoning
Authors: J. J. Alpert
Journal: BMJ (1964)

BJORNAL 1593 only one survivor has been reported from haemorrhage into the peritoneal cavity.Several surgical operations have been tried for this condition,3 such as excision of the aneurysm followed either by end-to-end suture of the hepatic artery or by anastomosis of the proximal end of the splenic artery (after splenectomy) with the distal end of the hepatic artery.We are grateful to Mr. J.
The Combination of Venetoclax and Tofacitinib Induced Hematological Responses in Patients with Relapse/ Refractory T-ALL with BCL2 Expression and Surface IL7R Expression or IL7R-Pathway Mutations (On behalf of the GRAALL)
Authors: Aurélie Cabannes, Aline Schmidt, Eolia Brissot, Marie Balsat, Sébastien Maury, Francoise Isnard, Patrice Chevallier, Victoria Cacheux, Thomas Cluzeau, Carlos Graux, Ludovic Lhermitte, Herve Dombret, Nicolas Boissel, Vahid Asnafi, Philippe Rousselot
Journal: Blood (2019)
STEM-07. THE ATYPICAL METALLOPROTEINASE ADAMDEC1 MAINTAINS A NOVEL FGF MEDIATED SIGNALLING NETWORK IN GLIOBLASTOMA CANCER STEM CELLS
Authors: Ana Jimenez-Pascual, James Hale, Defne Bayik, Daniel Silver, Gustavo Roversi, Tyler Alban, Thomas McIntyre, Giorgio Colombo, Giulia Taraboletti, Karl Holmberg, Karin Forsberg-Nilsson, Justin Lathia, Florian Siebzehnrubl
Journal: Neuro-Oncology (2019)

Abstract Glioblastomas (GBM) are lethal brain tumors where poor outcome is attributed to cellular heterogeneity, therapeutic resistance, and a highly infiltrative nature. These characteristics are preferentially linked to GBM cancer stem cells (CSCs), but how CSCs maintain their stemness is incompletely understood and the subject of intense investigation. CSCs rely both on cell intrinsic programs and microenvironmental interactions to regulate their maintenance. Recent work has demonstrated that CSCs can modulate their surrounding microenvironment by metalloproteinase expression, allowing direct modification of the extracellular matrix that provides structural tissue integrity, and instructive signalling via engagement of key cell surface receptors and sequestration of essential growth factors. Here, we identify a novel growth factor signalling loop that induces and maintains CSCs via an atypical metalloproteinase, a disintegrin and metalloproteinase domain-like protein decysin 1 (ADAMDEC1), secreted by CSCs. ADAMDEC1 solubilizes fibroblast growth factor-2 (FGF2) in the tumor microenvironment. We find that CSCs exclusively express FGF receptor 1 (FGFR1), which upon binding of FGF2 induces upregulation of Zinc finger E-box-binding homeobox 1 (ZEB1). ZEB1 is a regulator of stemness and tumor initiation, and therefore ADAMDEC1-FGF2-FGFR1 signalling promotes malignancy in GBM. We further show that ERK phosphorylation drives ZEB1, which regulates ADAMDEC1 expression, creating a positive feedback loop via repression of microRNA-203. Genetic or pharmacological targeting of components of this axis attenuates self-renewal and tumor growth. These findings reveal a new signalling axis for CSC maintenance and highlight ADAMDEC1 and FGFR1 as potential therapeutic targets in GBM. In addition, these findings provide a new paradigm for GBM growth through which key growth factors embedded within the extracellular matrix can be selectively accessed by CSC for their maintenance.
An All Antibody Approach for Conditioning Bone Marrow for Hematopoietic Stem Cell Transplantation with Anti-cKIT and Anti-CD47 in Non-Human Primates
Authors: Kristopher D Marjon, James Y Chen, Jiaqi Duan, Timothy S Choi, Kavitha Sompalli, Dongdong Feng, Ofelia Mata, Sharline Chen, Leslie Kean, Mwe Mwe Chao, Mark Chao, Chris H Takimoto, Balaji Agoram, Cynthia E. Dunbar, Ravi Majeti, Irving L Weissman, Jie Liu, Jens-Peter Volkmer
Journal: Blood (2019)
Treatment Intensity, Timing of Relapse and Outcome of 713 Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in a Population-Based Setting in Sweden
Authors: Karin Ekstrom Ekstroem Smedby, Sara Ekberg, Sandra Eloranta, Gunilla Enblad, Mats Jerkeman, Per-Ola Andersson, Sara Harrysson
Journal: Blood (2019)
A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
Authors: Anita Kumar, Carla Casulo, Ranjana H Advani, Lihua E Budde, Paul M. Barr, Connie Lee Batlevi, Philip Caron, Louis S. Constine, Savita Dandapani, Esther Drill, Pamela Drullinsky, Jonathan W. Friedberg, Clare Grieve, Audrey Hamilton, Paul A. Hamlin, Richard T Hoppe, Steven M. Horwitz, Matthew J Matasar, Susan Jennifer McCall, Alison J. Moskowitz, Ariela Noy, Maria Lia Palomba, Heiko Schoder, David J. Straus, Shreya Vemuri, Joanna C Yang, Anas Younes, Andrew D. Zelenetz, Joachim Yahalom, Craig H. Moskowitz
Journal: Blood (2019)
Evaluation of Immune Recovery Following Autologous Hematopoietic Cell Transplantation in HIV-Related Lymphoma: Results of the BMT CTN 0803/AMC 071 Trial
Authors: Mat Makowski, Elshafa Ahmed, Sarah Schlotter, Rebecca Pearson, Rhonda Kitzler, Joseph C. Alvarnas, Jennifer Le Rademacher, Yanli Wang, Richard F Little, Gorgun Akpek, Ernesto Ayala, Steven M. Devine, Lawrence D. Kaplan, Ariela Noy, Uday R. Popat, Jack W Hsu, Lawrence E. Morris, Jason Thompson, Mary H Horowitz, Adam M. Mendizabal, Alexandra M. Levine, Amrita Krishnan, Erinn Hade, Craig C Hofmeister, Stephen J. Forman, Willis H. Navarro, Richard F. Ambinder, Gerard Lozanski, Robert A Baiocchi
Journal: Blood (2016)